Pharmacodynamics of Meropenem and Imipenem Against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa

Pharmacotherapy

Volumn 24, Issue 1, 2004, Pages 8-15

  Kuti, Joseph L ^a   Florea, Naomi R ^a   Nightingale, Charles H ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Acinetobacter baumannii; Enterobacteriaceae; Imipenem; Meropenem; Monte Carlo simulation; Pharmacodynamics; Pseudomonas aeruginosa

Indexed keywords

CILASTATIN PLUS IMIPENEM; IMIPENEM; MEROPENEM;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; CALCULATION; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FRACTION OF UNBOUND DRUG; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MODEL; MONTE CARLO METHOD; NONHUMAN; PROBABILITY; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; SIMULATION; TERMINAL ELIMINATION RATE;

ACINETOBACTER BAUMANNII; CILASTATIN; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; HUMANS; IMIPENEM; INFUSIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA; THIENAMYCINS; TISSUE DISTRIBUTION;

EID: 0346096725     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.1.8.34804     Document Type: Article

References (33)

1. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001;47:247-50.
2. Pfaller MA, Jones RN, Biendenbach DJ. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn Microbiol Infect Dis 2001;41:177-82.
3. Jones RN. Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. J Antimicrob Chemother 2000;46:1-8.
4. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
5. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:73-101.
6. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42:521-7.
7. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998;27:10-22.
8. Walker R, Andes D, Conklin J, Ebert S, Craig W. Pharmacodynamic activities of meropenem in an animal infection model [abstr]. In: Programs and abstracts of the 34th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1994:147.
9. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003;36(suppl 1):S42-50.
10. Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000;38:151-7.
11. Kuti JL, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn Microbiol Infect Dis 2002;44:51-7.
12. Jones RN, Rubino CM, Bhavnani SM, Ambrose PG. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the antimicrobial resistance rate epidemiology study team. Antimicrob Agents Chemother 2002;47:292-6.
13. Kuti JL, Maglio D, Nightingale CH, Nicolau DP. Economic benefit of a meropenem dosing strategy based on pharmacodynamic concepts. Am J Health-Syst Pharm 2003;60:565-8.
14. Rhomberg PR, Jones RN, for the MYSTIC Program (USA) Study Group. Antimicrobial spectrum of activity for meropenem and nine broad-spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis 2003;47:365-72.
15. Astra-Zeneca LP. Data on file. Wilmington, DE; June 6, 2003.
16. Dreetz M, Hamacher J, Eller J, et al. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother 1996;40:105-9.
17. Mouton JW, Touw DJ, Horrevorts AM, Vinks AA. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000;39:185-201.
18. Astra-Zeneca Pharmaceuticals LP. Merrem (meropenem) package insert. Wilmington, DE, 2001.
19. Merck & Co, Inc. Primaxin (imipenem) package insert. West Point, PA, 1999.
20. Kays MB. Comparison of five β-lactam antibiotics against common nosocomial pathogens using the time above the MIC at different creatinine clearances. Pharmacotherapy 1999;19:1392-9.
21. Kays MB, Denys GA. In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics. Clin Ther 2001;23:413-24.
22. Nicolau DP. Using pharmacodynamic/pharmacokinetic surrogate markers in clinical practice: optimizing antibiotic therapy in respiratory tract infections. Am J Health-Syst Pharm 1999;56(suppl 3):S16-20.
23. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with gram-negative infections. J Antimicrob Chemother 2002;50:425-8.
24. Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 1997;41:2053-6.
25. Roosendaal F, Bakker-Woudenberg IAJM, Van Den Berghe-Van Raffe M, Michel MF. Continuous versus intermittent administration of Ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 1986;30:403-8.
26. Nicolau DP, McNabb JC, Lacy MK, Quintiliani R, Nightingale CH. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001;17:497-504.
27. Grant EM, Kuti JL, Nicolau DP, Nightingale CH, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002;22:471-83.
28. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979;67:608-16.
29. Kitzes-Cohen R, Farin D, Guillermo P, De Myttenaere-Bursztein SA. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 2002;19:105-10.
30. McKindley DS, Boucher BA, Hess MM, Croce MA, Fabian TC. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia. Pharmacotherapy 1996;16:924-31.
31. Kim MK, Capitano B, Mattoes HM, et al. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. Pharmacotherapy 2002;22:569-77.
32. Friedland I, Stinson L, Ikaiddi M, Harm S, Woods GL. Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acinetobacter: results of a multicenter intensive care unit surveillance study, 1995-2000. Diagn Microbiol Infect Dis 2003;45:245-50.
33. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003;47:1681-8.